Skip to main content

Advertisement

SpringerLink
Log in

Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate?

  • Kidney Diseases (G Ciancio, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The aim of this review was to summarize the evidence on the current role of cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma (mRCC).

Recent Findings

Since the advent of systemic targeted therapies for mRCC treatment, the role of CN has been questioned. Several retrospective observational studies demonstrated a therapeutic benefit for CN, while recent prospective randomized trials have challenged this evidence. As such, patient selection has become of paramount importance in this setting.

Summary

The role of CN on mRCC treatment is still object of debate. In carefully selected patients, CN remains an important option as a component of a multimodal therapeutic approach. As systemic therapies for mRCC continue to evolve, future trials are needed to evaluate the benefits and limits of CN in the immunotherapy era, tailoring the treatment sequence and selecting the patients who are most likely to benefit from surgical interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356. https://doi.org/10.1016/j.ejca.2018.07.005.

    Article  CAS  Google Scholar 

  2. Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. https://doi.org/10.1038/nrdp.2017.9.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74–84. https://doi.org/10.1016/j.eururo.2018.08.036.

    Article  PubMed  Google Scholar 

  4. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–9. https://doi.org/10.1056/NEJMoa003013.

    Article  CAS  PubMed  Google Scholar 

  5. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966–70. https://doi.org/10.1016/s0140-6736/01)06103-7.

    Article  CAS  PubMed  Google Scholar 

  6. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171:1071–6. https://doi.org/10.1097/01.ju.0000110610.61545.ae.

    Article  PubMed  Google Scholar 

  7. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354–66. https://doi.org/10.1056/NEJMra1601333.

    Article  CAS  PubMed  Google Scholar 

  8. • Bhindi B, Abel EJ, Albiges L, et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol. 2019;75(1):111-128. https://doi.org/10.1016/j.eururo.2018.09.016. The first systematic review of the evidence from multiple retrospective studies on the role of CN in mRCC treatment.

  9. •• Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417-427. https://doi.org/10.1056/NEJMoa1803675. A randomized phase 3 trial comparing sunitinib plus CN versus sunitinib alone in mRCC patients. For the first time, the non-inferiority of sunitinib alone versus systemic treatment plus cytoreductive surgery was shown.

  10. •• Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib. The SURTIME Randomized Clinical Trial. JAMA Oncol. 2019;5(2):164–170. https://doi.org/10.1001/jamaoncol.2018.5543. A randomized phase 3 trial comparing immediate CN versus deferred CN in mRCC treatment. Despite the limitation of low patient enrollment, the results showed better overall survival in deferred CN arm.

  11. •• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–1290. https://doi.org/10.1056/NEJMoa1712126. A randomized phase 3 trial demonstrating better overall survival and objective response rates in intermediate- and poor-risk mRCC patients treated with nivolumab plus ipilimumab compared to sunitinib.

  12. •• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116–1127. https://doi.org/10.1056/NEJMoa1816714. A randomized phase 3 trial demonstrating better overall survival and progression-free survival in mRCC patients treated with pembrolizumab plus axitinib compared to patients treated with sunitinib.

  13. •• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103-1115. https://doi.org/10.1056/NEJMoa1816047. A randomized phase 3 trial demonstrating better progression-free survival with avelumab plus axitinib than with sunitinib in mRCC patients.

  14. Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185:60–6. https://doi.org/10.1016/j.juro.2010.09.012.

    Article  PubMed  Google Scholar 

  15. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14:141–8. https://doi.org/10.1016/S1470-2045(12)70559-4.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014;66:704–10. https://doi.org/10.1016/j.eururo.2014.05.034.

    Article  PubMed  Google Scholar 

  17. Conti SL, Thomas IC, Hagedorn JC, et al. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer. 2014;134:2245–52. https://doi.org/10.1002/ijc.28553.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hanna N, Sun M, Meyer CP, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study. J Clin Oncol. 2016;34:3267–75. https://doi.org/10.1200/JCO.2016.66.7931.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Klatte T, Fife K, Welsh SJ, et al. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting. World J Urol. 2018;36:417–25. https://doi.org/10.1007/s00345-017-2154-x.

    Article  PubMed  Google Scholar 

  20. Palumbo C, Mistretta FA, Knipper S, et al. Contemporary cytoreductive nephrectomy provides survival benefit in clear-cell metastatic renal cell carcinoma. Clin Genitourin Cancer. 2020;6:730–8. https://doi.org/10.1016/j.clgc.2020.05.009.

    Article  Google Scholar 

  21. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454–63. https://doi.org/10.1200/JCO.2004.06.132.

    Article  PubMed  Google Scholar 

  22. Larcher A, Wallis C, Bex A, et al. Individualised indications for cytoreductive nephrectomy: which criteria define the optimal candidates? Eur Urol Oncol. 2019;4:365–78. https://doi.org/10.1016/j.euo.2019.04.007.

    Article  Google Scholar 

  23. Motzer RJ, Russo P. Cytoreductive nephrectomy – patient selection is key. N Eng J Med. 2018;379(5):481–2. https://doi.org/10.1056/NEJMe1806331.

    Article  Google Scholar 

  24. Ljungberg B, Albiges L, Bensalah K, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2020 Update. Eur Urol. 2020.

  25. De Bruijn RE, Mulders P, Jewett MA, et al. Surgical safety of cytoreductive nephrectomy following sunitinib: results from multicentre, randomised controlled trial of immediate versus deferred nephrectomy (SURTIME). Eur Urol. 2019;76(4):437–40. https://doi.org/10.1016/j.eururo.2019.06.006.

    Article  CAS  PubMed  Google Scholar 

  26. Graham J, Bhindi B, Heng DY. The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma. Curr Opin Urol. 2019;29:507–12. https://doi.org/10.1097/MOU.0000000000000657.

    Article  PubMed  Google Scholar 

  27. • Bhindi B, Graham J, Wells C, et al. Deferred cytoreductive nephrectomy in patients with newly diagnosed metastatic renal cell carcinoma. Eur Urol. 2020;78:615-623. https://doi.org/10.1016/j.eururo.2020.04.038. Although retrospective, this study evaluates the role of deferred CN in a large series of cases (n=1541), demonstrating an overall survival benefit associated with this treatment sequence.

  28. • De Bruijn R, Wimalasingham A, Szabados B, et al. Deferred cytoreductive nephrectomy following presurgical vascular endothelial growth factor receptor-targeted therapy in patients with primary metastatic clear cell renal cell carcinoma: a pooled analysis of prospective trial data. Eur Urol Oncol. 2020;3(2):168-173. https://doi.org/10.1016/j.euo.2019.12.004. Recent retrospective analysis of a cohort of 275 MSKCC intermediate-risk patients demonstrating an overall survival benefit associated with deferred CN.

  29. Tabakin A, Stein MN, Anderson CB, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma, the ultimate urologic “Chosing Wisely” campaign: a narrative review. Transl Cancer Res. 2020;9(11):7337–49. https://doi.org/10.21037/tcr-20-2343.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Shapiro D, Westerman ME, Karam JA, et al. Cytoreductive nephrectomy in patients presenting with advanced disease. Have we finally answered the question? Cancer J. 2020;26(5):382–389. https://doi.org/10.1097/PPO.0000000000000470.

  31. • Arora S, Sood A, Dalela D, et al. Cytoreductive nephrectomy: assessing the generalizability of the CARMENA trial to real-world National Cancer Data Base cases. Eur Urol. 2019;75:352–353. https://doi.org/10.1016/j.eururo.2018.10.054. A comparative analysis of the “real-world” mRCC population who underwent CN and the CARMENA population, showing significant differences between them and questioning the applicability of CARMENA trial results to clinical practice.

  32. Roussel E, Campi R, Larcher A, et al. Rates and predictors of perioperative complications in cytoreductive nephrectomy: analysis of the registry for metastatic renal cell carcinoma. Eur Urol Oncol. 2020;4:523–9. https://doi.org/10.1016/j.euo.2020.04.006.

    Article  Google Scholar 

  33. Kutikov A, Uzzo RG, Caraway A, et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int. 2010;106:218–23. https://doi.org/10.1111/j.1464-410X.2009.09079.x.

    Article  PubMed  Google Scholar 

  34. • Westerman ME, Shapiro DD, Tannir NM, et al. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int. 2020;126(6):745-753. https://doi.org/10.1111/bju.15160. The importance of this study resides in the demonstration that currently available prognostic models do not perform well in the setting of classifying mRCC patients in order to identify those who will benefit from surgical treatment.

  35. Liu WK, Lam JM, Grant M, et al. Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach. World J Urol. 2020;38:3199–205. https://doi.org/10.1007/s00345-020-03107-0.

    Article  CAS  PubMed  Google Scholar 

  36. Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010;116:3378–88. https://doi.org/10.1002/cncr.25046.

    Article  PubMed  Google Scholar 

  37. • McIntosh AG, Umbreit EC, Holland LC, et al. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer. 2020;126(17):3950-3960. https://doi.org/10.1002/cncr.32991. Recent update on the MDACC prognostic model, currently in need of external validation.

  38. Marchioni M, Kriegmair M, Heck M, et al. Development of a novel risk score to select the optimal candidate for cytoreductive nephrectomy among patients with metastatic renal cell carcinoma. Results from a Multi-institutional Registry (REMARCC). Eur Urol Oncol. 2020;S2588–9311(20)30218. https://doi.org/10.1016/j.euo.2020.12.010.

  39. Abel EJ, Spiess PE, Margulis V, et al. Cytoreductive nephrectomy renal cell carcinoma patients with venous tumor thrombus. J Urol. 2017;198:281–8. https://doi.org/10.1016/j.juro.2017.03.011.

    Article  PubMed  Google Scholar 

  40. Graham J, Wells JC, Donskov F, et al. Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. 2019;2(6):643–8. https://doi.org/10.1016/j.euo.2019.03.007.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Massari F, Di Nunno V, Gatto L, et al. Should CARMENA really change our attitude towards cytoreductive nephrectomy in metastatic renal cell carcinoma? A systematic review and meta-analysis evaluating cytoreductive nephrectomy in the era of targeted therapy. Target Oncol. 2018;13:705–14. https://doi.org/10.1007/s11523-018-0601-2.

    Article  PubMed  Google Scholar 

  42. Larcher A, Fallara G, Rosiello G, et al. Cytoreductive nephrectomy in metastatic patients with signs or symptoms: implications for Renal Cell Carcinoma Guidelines. Eur Urol. 2020;78(3):321–6. https://doi.org/10.1016/j.eururo.2020.05.014.

    Article  PubMed  Google Scholar 

  43. Bedke J, Albiges L, Capitanio U, et al. Updated European Association of Urology Guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma. Eur Urol. 2020;S0302–2838(20):30953–62. https://doi.org/10.1016/j.eururo.2020.12.005.

    Article  CAS  Google Scholar 

  44. Albiges L, Powles T, Staehler M, et al. Updated European Association of Urology Guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol. 2019;76(2):151–6. https://doi.org/10.1016/j.eururo.2019.05.022.

    Article  PubMed  Google Scholar 

  45. • Singla N, Hutchinson RC, Ghandour RA, et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National Cancer Database. Urol Oncol. 2020;38:604.e9-604.e17. https://doi.org/10.1016/j.urolonc.2020.02.029. The first retrospective analysis of the role of CN in the immunotherapy era, demonstrating an overall survival benefit in those patients treated with ICI plus CN compared to ICI alone.

  46. Meza L, Chehrazi-Raffle A, Pal SK. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered. Curr Opin Urol. 2020;30:740–2. https://doi.org/10.1097/MOU.0000000000000809.

    Article  PubMed  Google Scholar 

  47. Kim HL. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? No, cytoreductive nephrectomy should no longer be routinely performed. Curr Opin Urol. 2020;30:743–5. https://doi.org/10.1097/MOU.0000000000000812.

    Article  PubMed  Google Scholar 

  48. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications. Ann Surg. 2009;250:187–96. https://doi.org/10.1097/SLA.0b013e3181b13ca2.

    Article  PubMed  Google Scholar 

  49. Gershman B, Moreira DM, Boorjian SA, et al. Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy. Eur Urol. 2016;69:84–91. https://doi.org/10.1016/j.eururo.2015.05.022.

    Article  PubMed  Google Scholar 

  50. May DN, Hayden H, Matrana MR, et al. A contemporary analysis of the 30-day morbidity and mortality associated with cytoreductive nephrectomy. Urology. 2021;147:186–91. https://doi.org/10.1016/j.urology.2020.10.016.

    Article  PubMed  Google Scholar 

  51. Margulis V, Matin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008;180(1):94–8. https://doi.org/10.1016/j.juro.2008.03.047.

    Article  PubMed  Google Scholar 

  52. Harshman LC, Yu RJ, Allen GI, et al. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol Oncol. 2013;31(3):379–85. https://doi.org/10.1016/j.urolonc.2011.01.005.

    Article  CAS  PubMed  Google Scholar 

  53. Shinder BM, Rhee K, Farrell D, et al. Surgical management of advanced and metastatic renal cell carcinoma: a multidisciplinary approach. Front Oncol. 2017;7:107. https://doi.org/10.3389/fonc.2017.00107.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Pignot G, Thiery-Vuillemin A, Walz J, et al. Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: a new surgical challenge? Eur Urol. 2020;77(6):761–3. https://doi.org/10.1016/j.eururo.2019.12.018.

    Article  PubMed  Google Scholar 

  55. Ganeshappa A, Sundaram C, Lerner MA, et al. Role of the laparoscopic approach to cytoreductive nephrectomy in metastatic renal-cell carcinoma: does size matter? J Endourol. 2010;24:1289–92. https://doi.org/10.1089/end.2009.0401.

    Article  PubMed  Google Scholar 

  56. Mir MC, Matin SF, Bex A, et al. The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review. Minerva Urol Nefrol. 2018;70:109–25. https://doi.org/10.23736/S0393-2249.18.03055-2.

    Article  PubMed  Google Scholar 

  57. Nunez Bragayrac L, Hoffmeyer J, Abbotoy D, et al. Minimally invasive cytoreductive nephrectomy: a multi-institutional experience. World J Urol. 2016;34:1651–6. https://doi.org/10.1007/s00345-016-1827-1.

    Article  PubMed  Google Scholar 

  58. Gershman B, Thompson RH, Moreira DM, et al. Lymph node dissection is not associated with improved survival among patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma: a propensity score based analysis. J Urol. 2017;197:574–9. https://doi.org/10.1016/j.juro.2016.09.074.

    Article  PubMed  Google Scholar 

  59. Bhindi B, Wallis CJD, Boorjian SA, et al. The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. BJU Int. 2018;121:684–98. https://doi.org/10.1111/bju.14127.

    Article  PubMed  Google Scholar 

  60. Lyon TD, Thompson RH, Shah PH, et al. Complete surgical metastasectomy of renal cell carcinoma in the post-cytokine era. J Urol. 2020;203:257–82. https://doi.org/10.1097/JU.0000000000000488.

    Article  Google Scholar 

  61. Ouzaid I, Capitanio U, Staehler M, et al. Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol. 2019;2(2):141–9. https://doi.org/10.1016/j.euo.2018.08.028.

    Article  PubMed  Google Scholar 

  62. Zaid HB, Parker WP, Safdar NS, et al. Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. J Urol. 2017;197(1):44–9. https://doi.org/10.1016/j.juro.2016.07.079.

    Article  PubMed  Google Scholar 

  63. Dabestani S, Marconi L, Hofmann F, et al. Local treatment for metastases of renall cell carcinoma: a systematic review. Lancet Oncol. 2014;15(12):549–61. https://doi.org/10.1016/S1470-2045(14)70235-9.

    Article  Google Scholar 

  64. Bex A, Albiges L, Ljungberg B, et al. Updated European Association of Urology Guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma. Eur Urol. 2018;74(6):805–9. https://doi.org/10.1016/j.eururo.2018.08.008.

    Article  PubMed  Google Scholar 

  65. Motzer RJ, Jonasch E, et al. National Comprehensive Cancer Network Guidelines on Kidney Cancer: Version. 2020;1:2021.

    Google Scholar 

  66. Escudier B, Schmidinger M, Rioux-Leclercq N, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:706–20. https://doi.org/10.1093/annonc/mdz056.

    Article  CAS  PubMed  Google Scholar 

  67. Psutka SP, Master VA. Role of metastasis-directed treatment in kidney cancer. Cancer. 2018;124(18):3641–55. https://doi.org/10.1002/cncr.31341.

    Article  PubMed  Google Scholar 

  68. Bhanvadia S, Pal SK. Cytoreductive nephrectomy: questions remain after CARMENA. Nat Rev Urol. 2018;15(9):530–2. https://doi.org/10.1038/s41585-018-0064-3.

    Article  CAS  PubMed  Google Scholar 

  69. Kim HL, Mayerson E, Lara PN, et al. Considerations for the next clinical trial evaluating the role of cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol Focus. 2019;5(6):927–9. https://doi.org/10.1016/j.euf.2019.05.006.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Narayan VM, Dahm P. The future of clinical trials in urological oncology. Nat Rev Urol. 2019;16(12):722–33. https://doi.org/10.1038/s41585-019-0243-x.

    Article  CAS  PubMed  Google Scholar 

  71. Trinh QD, Bianchi M, Hansen J, et al. In-hospital mortality and failure to rescue after cytoreductive nephrectomy. Eur Urol. 2013;63(6):1107–14. https://doi.org/10.1016/j.eururo.2012.08.069.

    Article  PubMed  Google Scholar 

  72. Joshi SS, Handorf EA, Zibelman M, et al. Treatment facility volume and survival in patients with metastatic renal cell carcinoma: a registry-based analysis. Eur Urol. 2018;74(3):387–93. https://doi.org/10.1016/j.eururo.2018.05.025.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Hospital Clínico San Carlos, Complutense University of Madrid, Profesor Martín Lagos s/n, 28040, Madrid, Spain

    Roser Vives Dilme, Juan Gómez Rivas, Tamara Jerez & Jesús Moreno Sierra

  2. Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, Florence, Italy

    Riccardo Campi

  3. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

    Riccardo Campi

  4. European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, Netherlands

    Riccardo Campi

  5. Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain

    Javier Puente

  6. Institute of Urology and Reproductive Health, Sechenov University, Moscow, Russian Federation

    Dmitry Enikeev

  7. Department of Urology, University of Rome, Campus Biomedico, Rome, Italy

    Francesco Esperto

Authors
  1. Roser Vives Dilme
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juan Gómez Rivas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Riccardo Campi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Javier Puente
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tamara Jerez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dmitry Enikeev
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francesco Esperto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jesús Moreno Sierra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roser Vives Dilme.

Ethics declarations

Conflict of Interest

None.

ICJME Sect. 6 Statement — Payment for Expert Testimony

None.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Kidney Diseases

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dilme, R.V., Rivas, J.G., Campi, R. et al. Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate?. Curr Urol Rep 22, 54 (2021). https://doi.org/10.1007/s11934-021-01073-7

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11934-021-01073-7

Keywords

Search

Navigation